Several points may be worth mentioning as they relate to recent findings in the context of progressive MS trials. The effect of sphingosine 1-phosphate analogs is interesting in that one large study showed no significant effect in a cohort of primary progressive MS patients treated with fingolimod, 3 while a related compound (siponimod) did show an effect in secondary progressive MS patients. 4 It is unclear what drives this difference in two, almost concurrent studies, in progressive MS. Perhaps this relates to how the Expanded Disability and Status Scale (EDSS) was captured (paper and pencil format for former, and iPad ® based format with automated feedback for the latter), study population differences, or amount of underlying inflammatory disease, among others. This point illustrates that trial design holds a significant impact on the ultimate efficacy results of a given study. Subject selection may play a significant role and this has been exemplified by the results of the negative trial of rituximab 5 and positive result of ocrelizumab in primary progressive MS. In the ocrelizumab study, 6 subject selection was designed partially to mirror the subgroup where rituximab was most effective and the result was a positive trial.
The problem of outcome measures is not limited to phase 3 studies, but also to phase 2 studies. While gadolinium enhancing lesions are an excellent surrogate for relapses in relapsing-remitting multiple sclerosis (RRMS), 7 a similar predictive outcome is not available for progressive MS. The notion that the inadequacy of clinical trials in progressive MS was due to the wrong selection of therapeutics is a problem of phase II outcomes. As new more predictive outcomes are developed, therapeutics can be identified more efficiently (smaller sample sizes and shorter duration) to maximize the probability of success. The recent examples of using the visual system to look for remyelinating or neuroprotective drug effects is attractive and may be reproduced for either specific clinical scenarios or specific pathways. 8 Finally, significant work is needed to develop outcomes that are sensitive to change in relation to disease course, biological variability, mechanism of action of therapy, and expected timing of biological activity. For success in progressive MS, we need to improve not only the outcome measures, but also the therapeutic pathways tested, and the design and efficiency of clinical trials.
